PortugalPortugal

Network for Blue Biotech

07.06.2004

Faro - Recent advances in the field of genomics have opened up many exciting avenues of research. Marine biology, however, has largely been excluded from the so called “genomics revolution”. Until now: On May 11, during the EUROCEAN 2004 event in Galway, Ireland, details were presented of a Network of Excellence (NoE), newly established with funding from the Commission that aims to introduce the genomic approaches and technologies developed in other fields to the marine sciences.
One of the partners in the “Marine Genomics” NoE is Professor Adelino Canario, director of the Algarve centre of marine sciences at the University of Algarve in Portugal. “The aim of the Network is to integrate approaches throughout Europe,” he explained. “One example will be the development of high-throughput gene sequencing techniques for the study of marine biology.” This element of the project seeks to provide research centres throughout Europe with enabling technologies designed to identify the gene functions of a wide range of marine life.
“A further aspect of our work will be to provide marine researchers with access to technology platforms, comprising experimental equipment and databases that integrate the produced data. This is made possible through the participation in the NoE of a number of large research centres in countries like Germany, France and the UK,” said Professor Canario.
Indeed, the network as a whole brings together 44 institutes of varying size from 16 European countries, which ensures the involvement of some 300 researchers in total. In order to make this possible, the European Commission has invested Euro10 million in the scheme, under the “Sustainable development, global change and ecosystems” priority of the Sixth Framework Programme (FP6).
In addition to the scientific and technological elements of the project, emphasis will also be placed on the transfer of know-ledge to the wider research community through Europe.
In his own country, Portugal, Professor Canario hopes to encourage research centres and teams not involved in the network to adopt the technologies and approaches that will be developed, as for many of them it will be the first time they have used such techniques.

PortugalPortugal

03.11.2008

Poco Barreto – In mid-August, 60 anti-GMO activists destroyed a field planted with insect-resistant Mon810 maize in Portugal. Near the small Algarve town of Poco Barreto, activists from the “Movimento Verde Eufemia” trampled...

PortugalPortugal

19.08.2008

Lisbon – The international contract research organisation Chiltern sees potential for growth in Portugal. In May, it opened a new office in Lisbon that will be managed by Ricardo Diaz. Over the last two years, numbers of clinical...

PortugalPortugal

19.03.2008

Porto – 164 farmers planted a total of 4,199 hectares of genetically modified maize in Portugal in 2007, according to a report issued by the Portuguese Ministry of Agriculture. That represents a 330% increase compared to 2006,...

PortugalPortugal

22.11.2007

Cantanhede – Biogen Idec (Cambridge, US) and the Portuguese biopark Biocant in the Coimbra region have signed a socalled ‘Sponsored Research Agreement’ worth an undisclosed amount. Under the terms of the agreement, researchers...

Portugal, SpainPortugal

11.07.2007

Oeiras/Navarra – Portuguese antibody and genomics specialist Biotecnol SA and the Spanish university spin-off Digna Biotech will develop a process for manufacturing cardiotrophin-1 (CT-1) for the treatment of ischemic-reperfusion...

PortugalPortugal

11.07.2007

Porto – In September 2005, the Portuguese government established a decree law (No. 160/2005) on the co-existence between genetically modified organisms (GMO), conventional and organic crops. In short, it recommends a minimum...

PortugalPortugal

11.07.2007

Almada – transADVANcis Lda, a consultancy firm for nanotechnology and life sciences executives, has launched a website called www.nanogolive.com. With the new portal, on which anyone from the nanotechnology and life science...

PortugalPortugal

16.05.2007

Porto – Two Portuguese biotech companies have won the national idea contest for bio-entrepreneurs (Concurso de Ideias Bioempreendedor 2006), organized every year by the Portuguese Association of Bioindustries (APBio) and the...

PortugalPortugal

16.03.2007

Port Salvo – Biotrend S.A., developers of high-value compounds based in Lisbon, has closed a second investment round with the public venture capital outfit PME Investimientos, ending with a total investment exceeding 1 million...

PortugalPortugal

16.03.2007

Porto Salvo – Alfama, developers of small molecule drugs, has opened a laboratory in Boston, Massachusetts, in order to achieve US presence. The company will carry out research on the effects of self-developed molecules on...

Displaying results 11 to 20 out of 37

< Previous 11-20 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-portugal/browse/1/article/network-for-blue-biotech.html

Stock list

All quotes

TOP

  • ADDEX (CH)4.29 CHF18.51%
  • COSMO PHARMACEUTICALS (CH)179.10 CHF7.76%
  • NEUROVIVE PHARMACEUTICAL AB (S)55.75 SEK6.19%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • BAVARIAN NORDIC (D)15.82 EUR-8.02%

TOP

  • SANTHERA (CH)72.80 CHF117.6%
  • CELLECTIS (F)13.63 EUR101.0%
  • ADDEX (CH)4.29 CHF96.8%

FLOP

  • THROMBOGENICS (B)8.92 EUR-50.4%
  • MERCK KGAA (D)64.16 EUR-50.1%
  • VERONA PHARMA (UK)1.20 GBP-43.4%

TOP

  • SANTHERA (CH)72.80 CHF3209.1%
  • GW PHARMACEUTICALS (UK)444.50 GBP845.7%
  • PAION (D)2.83 EUR328.8%

FLOP

  • CYTOS (CH)0.25 CHF-92.8%
  • EVOCUTIS (UK)0.21 GBP-92.6%
  • THROMBOGENICS (B)8.92 EUR-72.2%

No liability assumed, Date: 10.07.2014

Job Advert

Executive Director of the IMI Joint Undertaking

The Innovative Medicines Initiative Joint Undertaking (IMI JU) is a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries Associations (EFPIA).
The Executive Director will lead and manage the Joint Undertaking and take overall responsibility for its operations ensuring the achievement of the Joint Undertaking's objectives. more...

Current issue

All issues

Product of the week

Products

Events

All Events